Events

Telix (ASX:TLX) has announced an exclusive commercial distribution agreement with Eckert & Ziegler for its prostate cancer imaging product Illuccix for the German market.

BioCurate and Monash University have announced the launch of Pio Therapeutics (Pio Tx) - a new company that will focus on developing novel, innovative and targeted medicines to improve outcomes for cancer patients.

AusBiotech presented today at the parliamentary inquiry into approval processes for new drugs and novel medical technologies in Australia, highlighting the long-term and stable biotech policy incentives needed to support and sustain R&D for treating rare diseases and conditions, where there is high and unmet clinical need.

AusBiotech is currently hosting its annual AusMedtech meeting that this year has the theme 'reimagine and reconnect'.

Sanofi and GSK have announced they will advance their two-shot adjuvanted recombinant COVID-19 vaccine to a phase three clinical trial.

MTPConnect has announced that the first REDI Fellowships have gone to researchers in South Australia and Queensland and urged the industry to get behind the program.

The NSW government has announced the first round of the Jobs Plus Program will deliver around 280 jobs with Baxter Healthcare and biotechnology company SpeeDx the first businesses to be part of the initiative.

Telix Pharmaceuticals (ASX:TLX) says it has been granted HREC approval and received CTN clearance by the TGA for a phase 3 clinical trial of its PSMA targeted prostate cancer therapy candidate TLX591 (177Lu-DOTA-rosopatamab).

Announcements in the 2021 Federal Budget are backing biotech and demonstrating the Government’s ongoing recognition of biotechnology as a long-term social and economic driver that will enhance Australia’s competitiveness, and keep us at the cutting edge of science and innovation.

Clinical-stage drug development company Dimerix (ASX:DXB) has provided an update on the CLARITY 2.0 study in COVID-19 patients in India.

Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder.

Australian clinical research organisation Avance Clinical has announced the expansion of its gene technology clinical trial service.